Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
AssigneeResearch Triangle Institute
InventorsRichard R. Tidwell, Edward J. Dubovi, Joachim D. Geratz
Life of this patent
Estimating the term…
Loading patent…
AssigneeResearch Triangle Institute
InventorsRichard R. Tidwell, Edward J. Dubovi, Joachim D. Geratz
Estimating the term…
A number of aromatic mono- and bis-amidines are capable of blocking cell fusion induced by Respiratory Syncytial (RS) virus. Suitable amidino compounds include those selected from the group consisting of 1-4-di(4-amidinophenoxy)-2-butanol; bis(5-amidino-2-benzimidazolyl)methane; 1,2-bis(5-amidino-2-benzimidazolyl )ethane; 5-amidino-indole; 5-amidinobenzimidazole, 5-amidino-1-methylindole and 5-amidino-1-(4-amidinobenzyl)indole. The most powerful of the compounds, bis(5-amidino-2-benzimidazolyl)methane (BABIM), is able to achieve complete suppression of syncytium formation at a concentration of 1 .mu.M. Inhibition occurs in RS virus-infected Hep-2 cells as well as CV-1 cells. BABIM also causes a significant retardation of RS virus penetration, but does not interfere with adsorption. Addition of the amidines after the penetration of RS virus does not affect single cycle yields. The compounds may be used in the prophylactic control of RS virus in man.
A method for the treatment of respiratory syncytial virus-induced cell fusion which comprises administering to a host in need of said treatment to an effective amount of an aromatic amidine compound selected from the group consisting of 5-amidinoindole and 5-amidino-1-methylindole.
Dependencies are inferred from the claim text.